SynthesisFrontiers in oncology2026
Predictors of pathological upstaging to pT3a after nephrectomy for cT1 renal tumors: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The potential predictors and clinical implications of postoperative pathological upstaging in patients with clinical stage T1 (cT1) renal cell carcinoma (RCC) remain insufficiently characterized. Methods: This systematic review was performed in accordance with the PRISMA guidelines. Databases including PubMed, Web of Science and Embase databases were searched. A total of 17 studies (involving 24957 patients) were included, and relevant factors were analyzed from the perspectives of patients' baseline characteristics, pathology, and imaging findings. Result: A total of 17 studies involving 24,957 patients were included. The overall incidence of pathological upstaging was 7.46%. Through combined qualitative and quantitative analysis, we identified the following independent risk associated factors for pathological upstaging to pT3a: male gender (OR: 1.067; 95% CI: 1.029-1.107;p=0.001), age (OR = 1.029; 95% CI: 1.02-1.038;p = 0.0001), BMI (OR:1.016;95% CI: 1.004-1.027;p=0.0001),cT1b (OR: 5.865; 95% CI: 3.711- 9.267; p = 0.0001),presence of clinical symptoms(OR:1.987; 95% CI: 1.439- 2.744; p = 0.0001), RENAL score= 7-9 (OR = 2.480; 95% CI: 1.516-4.058;p = 0.0001),necrosis on imaging(OR = 2.347;95% CI: 1.570-3.509;p = 0.0001), irregular margins (OR = 2.874; 95% CI: 1.760-4.693;p = 0.0001)and Hilus involvement (OR = 2.134;95%CI: 1.367-3.333;p = 0.001).Furthermore, the unadjusted meta-analysis results indicated an increased risk of recurrence in patients who upstaged to pT3a (HR = 3.50,95% CI = 2.00-6.13). After multivariable adjustment, the association remained consistent and in the same direction (HR = 2.60,95% CI = 1.86-3.64). Conclusion: Current evidence suggests that 9 variables, including advanced age, gender, and irregular margins may be predictors of postoperative pathological upstaging of cT1 RCC. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420250640397.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.